ES2044840T3 - Composiciones estabilizadas del activador del plasminogeno de tejido humano. - Google Patents

Composiciones estabilizadas del activador del plasminogeno de tejido humano.

Info

Publication number
ES2044840T3
ES2044840T3 ES86309811T ES86309811T ES2044840T3 ES 2044840 T3 ES2044840 T3 ES 2044840T3 ES 86309811 T ES86309811 T ES 86309811T ES 86309811 T ES86309811 T ES 86309811T ES 2044840 T3 ES2044840 T3 ES 2044840T3
Authority
ES
Spain
Prior art keywords
plasminogen activator
human tissue
tissue plasminogen
stabilized compositions
stabilized
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES86309811T
Other languages
English (en)
Inventor
William Franklin Bennett
Larry Alan Gatlin
Stuart Elliot Builder
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25205495&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2044840(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentech Inc filed Critical Genentech Inc
Application granted granted Critical
Publication of ES2044840T3 publication Critical patent/ES2044840T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/49—Urokinase; Tissue plasminogen activator
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

COMPOSICIONES ACEPTABLES FARMACEUTICAMENTE ESTABLES QUE CONTIENEN CARACTERISTICAS DE TEJIDO ACTIVADOR PLASMINOGENO HUMANO, POR EJEMPLO, UN ION ARGININIUM CONTENIENDO UN NIVEL DE UN COMPONENTE.
ES86309811T 1985-12-17 1986-12-16 Composiciones estabilizadas del activador del plasminogeno de tejido humano. Expired - Lifetime ES2044840T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US06/811,081 US4777043A (en) 1985-12-17 1985-12-17 Stabilized human tissue plasminogen activator compositions

Publications (1)

Publication Number Publication Date
ES2044840T3 true ES2044840T3 (es) 1994-01-16

Family

ID=25205495

Family Applications (1)

Application Number Title Priority Date Filing Date
ES86309811T Expired - Lifetime ES2044840T3 (es) 1985-12-17 1986-12-16 Composiciones estabilizadas del activador del plasminogeno de tejido humano.

Country Status (23)

Country Link
US (2) US4777043A (es)
EP (1) EP0228862B1 (es)
JP (2) JPH0714886B2 (es)
KR (1) KR950010322B1 (es)
AT (1) ATE79273T1 (es)
AU (1) AU600246B2 (es)
DD (1) DD255477A5 (es)
DE (2) DE3642960A1 (es)
DK (1) DK174203B1 (es)
ES (1) ES2044840T3 (es)
FI (1) FI88873C (es)
FR (1) FR2591485B1 (es)
GB (1) GB2184354B (es)
GR (1) GR3006078T3 (es)
HU (1) HU200101B (es)
IE (1) IE59060B1 (es)
IL (1) IL80904A (es)
MY (1) MY102185A (es)
NO (1) NO168988C (es)
NZ (1) NZ218612A (es)
PH (1) PH24716A (es)
PT (1) PT83933B (es)
ZA (1) ZA869457B (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3687255T2 (de) * 1985-09-10 1993-05-06 Eisai Co Ltd Einen gewebe-plasminogen-aktivator enthaltende zusammensetzung.
JPH0672105B2 (ja) * 1985-10-02 1994-09-14 持田製薬株式会社 血栓溶解剤及びその製法
US5453363A (en) * 1985-10-23 1995-09-26 Boehringer Mannheim Gmbh Process for the activation of t-PA or Ing after genetic expression in prokaryotes
US5034225A (en) * 1985-12-17 1991-07-23 Genentech Inc. Stabilized human tissue plasminogen activator compositions
JP2708749B2 (ja) * 1987-08-10 1998-02-04 エーザイ株式会社 修飾型ｔＰＡ含有注射用組成物
EP0317376B2 (fr) * 1987-10-23 1996-04-03 Centre Regional De Transfusion Sanguine De Lille Préparation de concentré de facteur IX humain de haute pureté et d'autres protéines plasmatiques
US4898826A (en) * 1987-12-10 1990-02-06 Invitron Corporation Method to solubilize tissue plasminogen activator
HU206367B (en) * 1988-04-30 1992-10-28 Sandoz Ag Process for producing acid addition salts of steroid carboxylic acid-amidated taurine and glycine, as well as pharmaceutical compositions comprising such salts
US4980165A (en) * 1989-01-27 1990-12-25 Genetics Institute, Inc. Pharmaceutical formulations of plasminogen activator proteins
DE3903581A1 (de) * 1989-02-07 1990-08-16 Boehringer Mannheim Gmbh Gewebs-plasminogenaktivator-derivat
JP2520975B2 (ja) * 1989-09-21 1996-07-31 三井東圧化学株式会社 組織プラスミノ―ゲンアクチベ―タ―若しくはその誘導体を含有する血栓溶解剤
US6207151B1 (en) * 1989-09-21 2001-03-27 Mitsui Chemicals Inc. Aqueous solution of t-PA
DE3942143A1 (de) * 1989-12-20 1991-06-27 Boehringer Mannheim Gmbh T-pa pro stabilisierung
DE3942142A1 (de) * 1989-12-20 1991-06-27 Boehringer Mannheim Gmbh Stabilisierung von glykosyliertem t-pa
DE3942141A1 (de) * 1989-12-20 1991-06-27 Boehringer Mannheim Gmbh K2p pro-stabilisierung
DE3942145A1 (de) * 1989-12-20 1991-06-27 Boehringer Mannheim Gmbh T-pa-solubilisierung
DE3942144A1 (de) * 1989-12-20 1991-06-27 Boehringer Mannheim Gmbh Stabilisierung von k1k2p pro
US5358708A (en) * 1993-01-29 1994-10-25 Schering Corporation Stabilization of protein formulations
US5656730A (en) * 1995-04-07 1997-08-12 Enzon, Inc. Stabilized monomeric protein compositions
DE19606551C2 (de) * 1996-02-22 2000-06-08 Basotherm Gmbh rt-PA zur Prävention des Nachstars nach Kataraktoperation
US5972912A (en) * 1998-12-17 1999-10-26 S.P. Pharmaceuticals Method for lyophilizing ifosfamide
DE60009926T2 (de) * 1999-08-17 2005-04-07 Novo Nordisk Health Care Ag Stabilisierung von gefriergetrocknetem kuchen
US6586574B1 (en) 1999-08-17 2003-07-01 Nn A/S Stabilization of freeze-dried cake
IL149006A0 (en) * 1999-11-04 2002-11-10 Genentech Inc Reversed-phase hplc for plasminogen activators
US7282219B2 (en) 2000-03-31 2007-10-16 Kirin Beer Kabushiki Kaisha Powdery preparation for transmucosal administration containing a polymeric form of drug and exhibiting improved storage stability
CN1553811A (zh) * 2001-09-07 2004-12-08 ӡ�����Ƽ��ɷ����޹�˾ 人组织尿激酶类型纤溶酶原激活物制剂
US20110179558A1 (en) * 2009-07-29 2011-07-28 International Enviroguard Systems, Inc. Breathable Protective Fabric and Garment
JP6649246B2 (ja) * 2013-03-14 2020-02-19 アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ タンパク質の徐放性送達の組成物及び製造プロセス中のタンパク質の安定化方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK98833C (da) * 1961-04-25 1964-05-25 Novo Terapeutisk Labor As Fremgangsmåde til stabilisering af terapeutisk anvendelige plasminopløsninger.
DE3273732D1 (en) * 1982-12-30 1986-11-20 Kowa Co Method of producing a tissue plasminogen activator and composition comprising same
JPS59196824A (ja) * 1983-04-21 1984-11-08 Kowa Co 吸着防止剤
DE3584902D1 (de) * 1984-02-29 1992-01-30 Asahi Chemical Ind Waessrige loesung eines darin in erhoehter konzentration aufgeloesten gewebe-plasminogen-aktivators und herstellungsverfahren.
GR861037B (en) * 1985-04-22 1986-07-16 Genentech Inc Novel human tissue plasminogen activator mutants
US4929444A (en) * 1985-05-28 1990-05-29 Burroughs Wellcome Co. Low pH pharmaceutical formulation containing t-PA
SE462893B (sv) * 1985-05-28 1990-09-17 Wellcome Found Vattenhaltig parenteral loesning av vaevnadsplasminogenaktivator och saett foer framstaellning av den
ZW14486A1 (en) * 1985-07-29 1986-10-22 Smithkline Beckman Corp Pharmaceutical dosage unit
DE3687255T2 (de) * 1985-09-10 1993-05-06 Eisai Co Ltd Einen gewebe-plasminogen-aktivator enthaltende zusammensetzung.
JPH0672105B2 (ja) * 1985-10-02 1994-09-14 持田製薬株式会社 血栓溶解剤及びその製法
DE3537708A1 (de) * 1985-10-23 1987-04-23 Boehringer Mannheim Gmbh Verfahren zur aktivierung von t-pa nach expression in prokaryonten
JPS62120321A (ja) * 1985-11-20 1987-06-01 Eisai Co Ltd ｔＰＡ含有医薬組成物
JPS62283932A (ja) * 1986-05-29 1987-12-09 Green Cross Corp:The 組織プラスミノ−ゲンアクチベ−タの乾燥製剤

Also Published As

Publication number Publication date
NO168988C (no) 1992-04-29
GB2184354A (en) 1987-06-24
DE3642960A1 (de) 1987-06-19
FI865159L (fi) 1987-06-18
IL80904A0 (en) 1987-03-31
IL80904A (en) 1992-01-15
ZA869457B (en) 1988-08-31
GB2184354B (en) 1990-04-11
GB8629981D0 (en) 1987-01-28
FI88873C (fi) 1993-07-26
IE59060B1 (en) 1993-12-15
FR2591485A1 (fr) 1987-06-19
HU200101B (en) 1990-04-28
ATE79273T1 (de) 1992-08-15
US4777043A (en) 1988-10-11
NO865079L (no) 1987-06-18
DD255477A5 (de) 1988-04-06
DK605786A (da) 1987-06-18
NO168988B (no) 1992-01-20
JPH0714886B2 (ja) 1995-02-22
GR3006078T3 (es) 1993-06-21
DK605786D0 (da) 1986-12-16
EP0228862B1 (en) 1992-08-12
PT83933B (pt) 1989-01-17
DE3686410D1 (de) 1992-09-17
JPH07173076A (ja) 1995-07-11
FI88873B (fi) 1993-04-15
AU6661086A (en) 1987-06-18
HUT42955A (en) 1987-09-28
IE863279L (en) 1987-06-17
NO865079D0 (no) 1986-12-16
PT83933A (en) 1987-01-01
NZ218612A (en) 1989-07-27
MY102185A (en) 1992-04-30
AU600246B2 (en) 1990-08-09
JPS62164632A (ja) 1987-07-21
KR870005647A (ko) 1987-07-06
DE3686410T2 (de) 1993-02-18
EP0228862A2 (en) 1987-07-15
FR2591485B1 (fr) 1989-07-28
EP0228862A3 (en) 1988-09-28
DK174203B1 (da) 2002-09-16
PH24716A (en) 1990-10-01
KR950010322B1 (ko) 1995-09-14
US4908205A (en) 1990-03-13
FI865159A0 (fi) 1986-12-17

Similar Documents

Publication Publication Date Title
ES2044840T3 (es) Composiciones estabilizadas del activador del plasminogeno de tejido humano.
ES2071486T3 (es) Derivado de la 5h-pirrolo(3,4-b)pirazina opticamente activa, su preparacion y las composiciones farmaceuticas que le contienen.
ES2055860T3 (es) Derivados 2-aminopirimidinona.
GR3007385T3 (es)
DK261490D0 (da) New pharmaceutical compound
ES2134801T3 (es) Monohidrato de hidrocloruro de tiagabina cristalina, su preparacion y su uso.
ES2054944T3 (es) Bis-(tri-t-alquilfenoxi) difosfaespiroundecanos.
ES2012573A6 (es) Una composicion fungicida activa en el control de hongos fitopatogenos, en particular oomicetos.
ES2044100T3 (es) Ciertas combinaciones de antagonistas del "paf" y antihistaminicos y metodos.
ES2053679T3 (es) Embonato de azelastina, procedimiento para su preparacion y preparados farmaceuticos que contienen embonato de azelastina como principio activo.
ES2076248T3 (es) Dibenzofuranos substituidos y metodos para el uso de los mismos.
TR22867A (tr) Birden fazla aktif bilesen ihtiva eden insektisid terkibi
ES2077698T3 (es) Agente terapeutico para la gangrena diabetica.
JO1493B1 (en) Pharmaceutical combination for treating high blood pressure
GR3003132T3 (en) Pharmaceutical compositions having healing activity
JPS55147220A (en) Hemostatic and thrombocyte number increaser comprising alpha,beta-diaminopropionic acid
ES8706441A1 (es) Procedimiento para preparar una composicion farmaceutica a base de sulpirida y un progestageno.
JO1531B1 (en) New near-compounds

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 228862

Country of ref document: ES